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Hexanucleotide repeat expansions (HREs) in C9orf72 are a major cause of frontotemporal
dementia (FTD) and amyotrophic lateral sclerosis (ALS). We aimed to determine the frequency
and phenomenology of movement disorders (MD) in carriers of HRE in C9orf72 through a
retrospective review of patients’ medical records.
Methods
We retrospectively reviewed the clinical records of patients carrying a C9orf72 HRE in the
pathogenic range and compared the characteristics of patients with and without MD.
Results
Seventeen of 40 patients with a C9orf72HRE had a documented MD. In 6 of 17, MD were the
presenting symptom, and in 2 of 17, MD were the sole manifestation of the disease. FTD was
present in 13 of 17 patients, ALS in 5 of 17 patients, and 2 of 17 patients did not develop FTD or
ALS. Thirteen of 17 patients had more than one MD. The most common MD were parkin-
sonism and tremor (resembling essential tremor syndrome), each one present in 11 of 17
patients. Distal, stimulus-sensitive upper limbs myoclonus was present in 6 of 17 patients and
cervical dystonia in 5 of 17 patients. Chorea was present in 5 of 17 patients, 4 of whom showed
marked orofacial dyskinesias. The most frequent MD combination was tremor and parkin-
sonism, observed in 8 of 17 patients, 5 of whom also had myoclonus. C9orf72 patients without
MD had shorter follow-up times and higher proportion of ALS, although these results did not
survive the correction for multiple comparisons.
Conclusions
MD are frequent in C9orf72. They may precede signs of ALS or FTD, or even be present in
isolation. Parkinsonism, tremor, and myoclonus are most commonly observed.
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The GGGGCChexanucleotide repeat expansion (HRE) in the
C9orf72 gene is the most frequent genetic cause of fronto-
temporal dementia (FTD) and amyotrophic lateral sclerosis
(ALS).1,2 Movement disorders (MD) are frequently observed
in C9orf72 HRE carriers,3 generally alongside the features of
FTD or ALS, with parkinsonism being present in up to 40%.4
The prevalence of C9orf72 HRE in other MD has also been
investigated. There is no association between C9orf72 HRE
and Parkinson disease5 or essential tremor syndrome (ETS).6
Conversely, C9orf72 HRE seems over-represented in corti-
cobasal syndrome (CBS)7 and is the most frequent Hun-
tington disease phenocopy.8
In this study, we sought to define the MD associated with
HRE in the C9orf72 gene and compared the characteristics of
C9orf72 patients with and without MD.
Methods
Standard Protocol Approvals, Registrations,
and Patient Consents
All participants were recruited under ethics-approved re-
search protocol (UCLH: 04/N034). Clinical records of all
patients with HRE in C9orf72 tested at the National Hos-
pital for Neurology and Neurosurgery between May 2012
and May 2019 were retrospectively reviewed. Filmed pa-
tients provided written informed consent before video
recording.
Genetic Analysis
Repeat-primed fluorescent PCR (RP-PCR) was performed as
previously reported in the study by Renton et al. to test for the
presence of an expansion in C9orf72.1 An ABI (Carlsbad, CA)
3730xl automated sequencer was used for fragment length
analysis through capillary electrophoresis. Analysis of RP-
PCR electropherograms was performed using Peak Scanner
v1.0 (ABI). Expansions with a characteristic sawtooth pattern
were put forward for Southern blotting.
Southern hybridization9was performed by combining the use of a
(GGGGCC)5 probe targetingmultiple sites within the expansion
and genomic DNA digested with 2 frequently cutting restriction
endonucleases whose sites closely flanked the repeat region.
Expansion size was estimated by interpolation of autoradiographs
using a plot of log10 base pair number against migration distance.
A minimal size of 30 GGGGCC repeats in the C9orf72 gene
was defined as pathogenic.10 The expansions were classified as
“small” if patients had between 30 and 90 GGGGCC repeats
and “large” if there were >90 GGGGCC repeats.
Statistical Analysis
Quantitative data were not normally distributed after visual
evaluation of the data and using the Shapiro-Wilk test.
Statistical testing was subsequently performed using the
Mann-Whitney U test. Fisher exact test was used to compare
proportions. The results were corrected for multiple com-
parisons using the Benjamini-Hochberg false discovery rate
(FDR), with FDR <0.05 deemed a significant result.
Analyses were performed using Stata version 12.0 (StataCorp,
College Station, TX).
Data Availability
Anonymized data not published in this article will be available
from the corresponding author on reasonable request.
Results
Patients
A total of 501 patients underwent C9orf72 HRE testing. Of
these, 53 patients had more than 30 repeats. Clinical data were
available in 40 of 53 patients. Among the 40 patients with HRE
and available data, 17 had MD according to their clinical notes
(table 1; figure e-1, links.lww.com/NXG/A394).
Patients who developed MD were referred to the neurology
clinics because of either MD (7/17) or cognitive symptoms (9/
17), or both (1/17). Genetic analysis of C9orf72 was requested
because of the combination of MD and cognitive symptoms (4/
17), cognitive symptoms and family history of neurodegenera-
tive conditions (7/17), MD and positive family history (2/17),
isolated MD (3/17), and isolated cognitive symptoms (1/17).
Among patients with MD and HRE, C9orf72 testing was
requested from consultant neurologists from the cognitive (8/
17), MD (6/17) general neurology (2/17), and neuromuscular
clinics (1/17). Of the 17 patients with C9orf72HRE and MD, 2
of 17 had small HREs and the remainder had large expansions in
C9orf72. Seven of 17 patients (41.18%)werewomen.Median age
at onset in patients withMDwas 58 years (range 8–70). A family
history of dementia or ALS in first-degree relatives was present in
64.7% of the cases withMD and 69.5% of the cases withoutMD.
Neuropsychometry
Fourteen of 17 patients with MD had available neuro-
psychological assessments (table 2). Among them, 10 of 14
presented executive dysfunction and/or memory impairment,
Glossary
AAO = age at onset; ALS = amyotrophic lateral sclerosis; CBS = corticobasal syndrome; ETS = essential tremor syndrome;
FDR = false discovery rate; FTD = frontotemporal dementia; HRE = hexanucleotide repeat expansion; MD = movement
disorder.
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whereas 7 of 14 had slow processing speed. Either visuospatial
dysfunction, impaired calculation, or attention deficits were
present in 2 of 14 patients, whereas 4 of 14 patients had de-
creased verbal fluency.
Neuroimaging
Fifteen of 17 patients had available brain MRI reports. Find-
ings included generalized atrophy in 7 of 15 patients, frontal
atrophy in 2 of 15 patients, small vessel disease in 2 of 15
patients, and 1 of 15 patient had midbrain atrophy. The
remaining 3 of 15 patients had a normal MRI. No patients
exhibited asymmetric atrophy.
Symptom Onset and Progression
MDwere the initial disease manifestation in 6 of 17 patients: 1
presented with cerebellar ataxia, 1 with hemichorea, 1 with
cervical dystonia, and 3 with parkinsonism. Among the other
11 patients, 8 presented with cognitive symptoms (7 with
FTD and 1 with learning disabilities) and 3 had a psychiatric
onset (1 recurrent panic attacks, 1 psychotic episode, and 1
schizoid personality disorder). In patients who did not pre-
sent with MD, median time from first symptom to de-
velopment of MD was 3.5 years (range 0–11 years).
During the follow-up, 10 of 17 patients developed FTD, 2 of
17 developed ALS, and 3 of 17 developed FTD/ALS overlap.
The 2 patients who continued to exhibit solely MD features at
the last follow-up had the earliest age at onset (AAO).
Movement Disorders
Most patients (13/17) had more than one MD. The most
frequent combination was tremor and parkinsonism (8/17
patients), 5 of whom also had myoclonus.
Tremor and parkinsonism were equally prevalent MD man-
ifestations in this cohort, each one affecting 11 of 17 patients
(table 1; figure 1). Phenomenologically, tremor usually re-
sembled ETS (8/11) as low-amplitude, high-frequency pos-
tural and intention tremor affecting the upper limbs
symmetrically. Other phenotypes, occasionally overlapping
with ETS-like tremor, included “jerky” arm tremor (2/11),
rest tremor affecting the arms alone (2/11) or legs with later
progression to the arms (3/11), tongue tremor (1/11), and
isolated “no-no” head tremor (1/11).
Parkinsonism was mild in 9 of 11 patients and severe and
rapidly progressive in the remaining 2 patients, leading them







MD, y FTD ALS Tremor Myoclonus Parkinsonism Ataxia Dystonia Chorea
1a Female Small 64 64 + − + − + + + −
2a Male Small 70 70 − + + + + − − −
3 Male Large 60 60 + − − + − − − +
4 Female Large 58 58 + − + + + − − −
5 Male Large 8 18 − − − + − − + +
6 Male Large 53 56 + − + − + − − −
7 Female Large 54 61 + − + − − − + −
8 Male Large 39 50 + + + + + − − −
9 Male Large 59 69 + + + − − − − −
10a Female Large 55 55 + − − − + − − −
11a Female Large 58 58 − + + − + − + +
12 Male Large 69 72 + − − − + − − −
13a Female Large 40 40 + − + − + − + −
14a Male Large 19 19 − − − − − − − +
15 Male Large 36 41 + + + + + − + −
16 Female Large 62 66 + − + + + − − −














51.86 (17.8) 57.27 (10.60) 64 49 (16.8) 43.2
(22.6)
Abbreviations: AAO = age at onset; ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia; MD = movement disorder.
a Patients who had MD as the first manifestation of C9orf72 expansions.
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to become bedbound within a year from onset. Parkinsonism
was asymmetric in 6 of 11 patients; 3 of 11 patients received a
clinical diagnosis of CBS (video 1, segment 1, links.lww.com/
NXG/A396). DaTscan was performed in 3 of 11 patients and
was abnormal in all. Levodopa was administered to all 3 pa-
tients with abnormal DaTscan, providing subjective benefit in
2. One patient without available DaTscan did not improve
with levodopa.
Myoclonus was present in 7 of 17 patients. In most (6/7
patients), this manifested as distal stimulus-sensitive
jerks affecting both upper limbs (video 1, segment 1,
links.lww.com/NXG/A396), whereas one patient was
considered to have isolated myoclonus of the cheek by a
MD specialist.
Dystonia was observed in 7 of 17 patients during the follow-
up. In 5 of 7, it exclusively involved the cervical region,
whereas one patient had hemidystonia and another had dys-
tonic posturing of the arms.
Five patients had chorea, which was limited to the perioral
region in 2 patients, to one hemibody in another, and
generalized in 2. There were marked orofacial dyskinesias
in 4 of 5 patients with chorea (video 1, segment 2, links.
lww.com/NXG/A396) resembling tardive dyskinesia, al-
though only one patient had a previous history of neuro-
leptic exposure. One patient had prominent appendicular
ataxia.
Seizures occurred in 4 of 17 patients. Further details are
available in the table e-1 (links.lww.com/NXG/A395).
Comparison Between C9orf72 Patients With
and Without MD
Patients with HRE and MD (MD+) had a lower proportion of
ALS compared with patients with HRE without MD (MD−) (5/
17 in MD+ vs 17/23 MD−), a higher proportion of FTD (13/17
MD+ as opposed to 11/23 MD−) and longer median follow-up
times (8 years in MD+ compared with 3 years in MD−). Median
time from onset to death was longer in the patients with HRE and
MD than in those without MD (8 years in MD+ vs 2.5 years in
MD−). A family history of neurodegenerative disorders did not
differ between cohorts (11/17 MD+ vs 16/23 MD−) (table 3).
Noneof this results survived correction formultiple comparisons at
a pFDR = 0.05.
Discussion
This study examined the MD associated with HRE in C9orf72
and the differences between HRE carriers with and without
MD. Our findings suggest that MD are frequent in patients
with HRE in C9orf72 and often precede FTD/ALS. More-
over, MD can be the initial or even the sole manifestation of
C9orf72 HRE. Consequently, the spectrum of MD may be
significantly more diverse than previously appreciated.
Tremor and parkinsonism were the most frequent MD in our
cohort. Although rest tremor has previously been reported in
HRE carriers with parkinsonism, postural and intentional
tremor, frequently observed in our study, were only men-
tioned in one previous study as being rare.4,8
Parkinsonism is a well-recognized feature of the C9orf72HRE
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However, in 2 patients, levodopa-unresponsive parkinsonism
was the cardinal clinical feature and exhibited a rapidly pro-
gressive course, which has not previously been reported.
Symmetric, stimulus-sensitive upper limb myoclonus, frequently
coexisting with parkinsonism, and chorea with marked orofacial
involvement were also a common finding in our cohort.
Despite MD being frequent in C9orf72 HRE carriers, the phe-
notypic manifestations do not fall neatly into other syndromic
categories, e.g., progressive supranuclear palsy andmultiple system
atrophy. It is therefore unlikely that misdiagnosis as neurodegen-
erative entities other thanFTDorALSwould occur.2This perhaps
explains the low frequency of C9orf72 HRE among patients
with clinical diagnoses of other neurodegenerative conditions.7,11
None of the contrasts between C9orf72 HRE with and without
MD survived multiple comparisons correction. This may be re-
lated to the small sample sizes in both cohorts (MD+ andMD−),
which is inherent to the low frequency of C9orf72 expansions.
Figure 1 Distribution of Movement Disorders in Patients With Hexanucleotide Repeat Expansions in C9orf72
Table 3 Comparison Between Patients With and Without MD
MD-positive (n = 17) MD-negative (n = 23)
Raw p value FDRMedian IQR Median IQR
AAO, y 58 40–60 60 54–63 0.166 Not significant
Onset to death, y (n = 6) 8 5–11 (n = 14) 2.5 2–6 0.166 Not significant
Follow-up, y 8 4–11 3 2–6 0.021 Not significant
Onset to MD, y 3.5 0.5–8.5 N/A N/A N/A N/A
Age at last visit, y 66 59–69 65 56–69 0.974 Not significant
n (%) n (%)
FTD 13 (76.5) 11 (47.8) 0.104 Not significant
ALS 5 (29.4) 17 (73.9) 0.010 Not significant
FH 11 (64.7) 16 (69.5) 0.341 Not significant
Seizures 4 (23.5) 0 (0) 0.008 Not significant






Abbreviations: AAO = age at onset; ALS = amyotrophic lateral sclerosis; FH = family history of ALS or dementia in first-degree relatives; FDR = false discovery
rate; FTD = frontotemporal dementia; IQR = interquartile range; MD = movement disorder; N/A = not applicable.
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However, MD were less common in those presenting with ALS
phenotypes. This may simply reflect shorter follow-up times and
difficulty in identifying certainMD in the context of ALS.1,2,10 Of
note, the 2 sole patients who did not develop FTD or ALS had
the earlier AAO, being therefore possible that either of these
conditions is developed during the follow-up.
Our study has several limitations, mainly derived from its retro-
spective nature. Video recordings were only available in 2 patients,
information about previous medications was not systematically
recorded in medical notes, and none of our patients had neuro-
physiologic studies performed. Furthermore, most of the patients
were unable to visit our hospital for a clinical review. Clinical data
therefore had to be obtained from the medical record and/or
discussion with the treating consultant whenever necessary.
Our results suggest that C9orf72-associated MD are clinically
heterogeneous and frequently found in combination. ETS-like
tremor, parkinsonism, distal myoclonus, chorea with orofacial
involvement, and cervical dystonia in the context of familial
neurodegenerative conditions should prompt molecular ge-
netic testing of the C9orf72 gene. Further prospective, sys-
tematic studies are needed to accurately assess the phenotypic
manifestations of C9orf72-associated MD.
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